Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fexofenadine - sanofi-aventis

Drug Profile

Fexofenadine - sanofi-aventis

Alternative Names: Allegra; Allegra-D; Fexofenadine; Fexohf-1-96; M016455; MDL 16455; MDL 16455A; Telfast; Telfast 120; Telfast 180; TelfastPaediatric; Terfenadine acid metabolite; Terfenadine carboxylate

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Acetic acids; Antiallergics; Benzhydryl compounds; Nonsedating antihistamines; Piperidines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Atopic dermatitis; Chronic urticaria; Dermatitis; Perennial allergic rhinitis; Pruritus; Seasonal allergic rhinitis
  • Discontinued Asthma

Most Recent Events

  • 23 Jan 2023 Sanofi initiates the phase III FEXPRESAR proof of concept trial for Seasonal allergic rhinitis (In adults, In the elderly) in Canada (PO, Tablet) (NCT05692154)
  • 16 Jan 2023 Sanofi plans a phase III FEXPRESAR proof of concept trial for Seasonal allergic rhinitis (In adults, In the elderly) (PO, Tablet) (NCT05692154)
  • 03 Jan 2019 Sanofi completes a phase III trial in Seasonal allergic rhinitis in Canada (PO) (NCT03664882)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top